Corcept Therapeutics Incorporated (CORT)

US — Healthcare Sector
Peers: CRNX  ENTA  FOLD  CNTB  CYTK  SUPN  VNDA  INVA 

Automate Your Wheel Strategy on CORT

With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CORT
  • Rev/Share 6.5841
  • Book/Share 6.5634
  • PB 11.1376
  • Debt/Equity 0.01
  • CurrentRatio 3.065
  • ROIC 0.1297

 

  • MktCap 7751889500.0
  • FreeCF/Share 1.7018
  • PFCF 43.7557
  • PE 57.2816
  • Debt/Assets 0.0081
  • DivYield 0
  • ROE 0.2046

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
CORT
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
CORT
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Corcept Therapeutics, Inc. (NASDAQ:CORT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Joe Belanoff - Co-Founder, President, CEO & Director Bill Guyer - Chief Development Officer Sean Maduck - President, Endocrinology Conference Call Participants David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Asim Rana - Truist Operator Thank you for standing by, and welcome to Corcept Therapeutics conference call.

Read More
image for news Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript

About Corcept Therapeutics Incorporated (CORT)

  • IPO Date 2004-04-14
  • Website https://www.corcept.com
  • Industry Biotechnology
  • CEO Joseph K. Belanoff
  • Employees 500
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.